Vaxcyte, Inc. 8-K

What Happened
Vaxcyte, Inc. announced an underwritten public offering of common stock that closed on February 2, 2026. The company sold 11,000,000 shares at $50.00 per share to the public and granted the underwriters a 30‑day option for an additional 1,650,000 shares, which the underwriters exercised in full on January 30, 2026. The underwriters (led by BofA Securities, Jefferies, Leerink Partners and Evercore) purchased the shares from Vaxcyte at $47.50 per share. Net proceeds to Vaxcyte, after underwriting discounts, commissions and estimated expenses, were approximately $600.2 million. The offering was made under Vaxcyte’s effective Form S-3 registration statement.

Key Details

• Offering size: 11,000,000 shares sold by Vaxcyte; underwriters exercised full 30‑day option for 1,650,000 additional shares (total 12,650,000 shares).
• Price: $50.00 per share to the public; underwriter purchase price $47.50 per share.
• Net proceeds: approximately $600.2 million after underwriting discounts, commissions and estimated offering expenses.
• Closing and timing: Underwriters exercised overallotment on Jan 30, 2026; offering closed on Feb 2, 2026. Legal opinion and underwriting agreement were filed as exhibits to the 8‑K.

Why It Matters
This transaction materially increases Vaxcyte’s cash resources, providing significant funding that can support operations, clinical development and other corporate activities without immediate dilution from debt. For investors, the offering affects share count and ownership (primary issuance), and the company’s strengthened balance sheet may reduce near‑term financing risk. The filing is procedural disclosure of the financing and the related underwriting agreement and legal opinions.